Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Connect Biopharma Holdings (CNTB) EPS (Weighted Average and Diluted) (2024 - 2025)

Connect Biopharma Holdings (CNTB) has disclosed EPS (Weighted Average and Diluted) for 2 consecutive years, with -$0.27 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) fell 68.75% to -$0.27 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.0 through Dec 2025, down 257.14% year-over-year, with the annual reading at -$1.0 for FY2025, 257.14% down from the prior year.
  • EPS (Weighted Average and Diluted) hit -$0.27 in Q4 2025 for Connect Biopharma Holdings, up from -$0.31 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.27 in Q2 2024 to a low of -$0.31 in Q3 2025.